Zhang, Wen-Wei http://orcid.org/0000-0003-1996-876X
Karmakar, Subir
Gannavaram, Sreenivas
Dey, Ranadhir
Lypaczewski, Patrick http://orcid.org/0000-0002-5550-712X
Ismail, Nevien
Siddiqui, Abid
Simonyan, Vahan http://orcid.org/0000-0002-4868-4785
Oliveira, Fabiano http://orcid.org/0000-0002-7924-8038
Coutinho-Abreu, Iliano V. http://orcid.org/0000-0002-1389-1071
DeSouza-Vieira, Thiago
Meneses, Claudio
Oristian, James
Serafim, Tiago D.
Musa, Abu http://orcid.org/0000-0003-0662-0078
Nakamura, Risa
Saljoughian, Noushin
Volpedo, Greta
Satoskar, Monika
Satoskar, Sanika
Dagur, Pradeep K.
McCoy, J. Philip
Kamhawi, Shaden http://orcid.org/0000-0003-4304-636X
Valenzuela, Jesus G. http://orcid.org/0000-0002-5589-9450
Hamano, Shinjiro
Satoskar, Abhay R. http://orcid.org/0000-0001-5989-1520
Matlashewski, Greg http://orcid.org/0000-0002-8971-5525
Nakhasi, Hira L. http://orcid.org/0000-0003-4941-1620
Funding for this research was provided by:
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre
https://www.ghitfund.org/
Article History
Received: 17 January 2019
Accepted: 13 June 2020
First Online: 10 July 2020
Competing interests
: The FDA is currently a co-owner of two US patents that claim attenuated <i>Leishmania</i> species with the Centrin gene deletion (US7,887,812 and US 8,877,213). All other authors declare they have no competing interests.